deferiprone has been researched along with Cardiac Failure in 18 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Reversal of arrhythmia to sinus rhythm was noted in all patients." | 5.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 5.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 5.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "A 20-year-old male affected by transfusion-dependent β-thalassemia (β-thal), was prescribed intensive chelation therapy with deferoxamine (DFO) and deferiprone (DFP) because of severe hepatic and cardiac iron overload and β-blocker and warfarin to manage a previous event of atrial fibrillation (AFib) and heart failure." | 3.88 | Life-Threatening Drug-Induced Liver Injury in a Patient with β-Thalassemia Major and Severe Iron Overload on Polypharmacy. ( Casale, M; Cerasari, G; Corvino, F; Perrotta, S; Persico, M; Picariello, S; Rossi, F; Scianguetta, S, 2018) |
| " In thalassemia major patients, combined therapy with desferrioxamine and deferiprone has maximized tissue iron removal and may reduce the overall occurrence of hemosiderotic heart failure." | 3.73 | Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia. ( Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Moyssakis, I; Polonifi, K; Tsironi, M, 2005) |
| "The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination." | 3.73 | Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2006) |
| "Treatment with deferasirox significantly improves left ventricular function." | 2.77 | Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. ( Brevi, F; Cappellini, MD; Cassinerio, E; Graziadei, G; Milazzo, A; Pattoneri, P; Pedrotti, P; Roghi, A; Zanaboni, L, 2012) |
| "Reversal of arrhythmia to sinus rhythm was noted in all patients." | 1.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
| "In patients with thalassemia major (TM) who are non-compliant with long-term desferrioxamine (DFO) chelation, survival is limited mainly because of cardiac complications of transfusional hemosiderosis." | 1.33 | Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. ( Aessopos, A; Andriopoulos, P; Deftereos, S; Farmakis, D; Meletis, J; Tsironi, M, 2005) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 1.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 1.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chuang, TY | 1 |
| Li, JP | 1 |
| Weng, TF | 1 |
| Wu, KH | 3 |
| Chao, YH | 1 |
| Casale, M | 1 |
| Picariello, S | 1 |
| Corvino, F | 1 |
| Cerasari, G | 1 |
| Scianguetta, S | 1 |
| Rossi, F | 1 |
| Persico, M | 1 |
| Perrotta, S | 1 |
| Porter, JB | 1 |
| Wood, J | 1 |
| Olivieri, N | 1 |
| Vichinsky, EP | 1 |
| Taher, A | 1 |
| Neufeld, E | 1 |
| Giardina, P | 1 |
| Thompson, A | 1 |
| Moore, B | 1 |
| Evans, P | 1 |
| Kim, HY | 1 |
| Macklin, EA | 1 |
| Trachtenberg, F | 1 |
| Origa, R | 1 |
| Danjou, F | 1 |
| Cossa, S | 1 |
| Matta, G | 1 |
| Bina, P | 1 |
| Dessì, C | 2 |
| Defraia, E | 1 |
| Foschini, ML | 1 |
| Leoni, G | 1 |
| Morittu, M | 1 |
| Galanello, R | 2 |
| Tauchenová, L | 1 |
| Křížová, B | 1 |
| Kubánek, M | 1 |
| Fraňková, S | 1 |
| Melenovský, V | 1 |
| Tintěra, J | 1 |
| Kautznerová, D | 1 |
| Malušková, J | 1 |
| Jirsa, M | 1 |
| Kautzner, J | 1 |
| Cassinerio, E | 1 |
| Roghi, A | 1 |
| Pedrotti, P | 1 |
| Brevi, F | 1 |
| Zanaboni, L | 1 |
| Graziadei, G | 1 |
| Pattoneri, P | 1 |
| Milazzo, A | 1 |
| Cappellini, MD | 2 |
| Chang, JS | 2 |
| Tsai, CH | 1 |
| Peng, CT | 2 |
| Tsironi, M | 2 |
| Deftereos, S | 2 |
| Andriopoulos, P | 2 |
| Farmakis, D | 2 |
| Meletis, J | 1 |
| Aessopos, A | 2 |
| Polonifi, K | 1 |
| Moyssakis, I | 1 |
| Pennell, DJ | 2 |
| Martín, M | 1 |
| Estornell, J | 1 |
| Orero, M | 1 |
| Pérez, JL | 1 |
| Ridocci, F | 1 |
| Martínez, V | 1 |
| Tavecchia, L | 1 |
| Masera, N | 1 |
| Russo, P | 1 |
| Cirò, A | 1 |
| Vincenzi, A | 1 |
| Vimercati, C | 1 |
| Masera, G | 1 |
| Kolnagou, A | 2 |
| Economides, C | 1 |
| Eracleous, E | 1 |
| Kontoghiorghes, GJ | 2 |
| Huang, YC | 1 |
| Fabio, G | 1 |
| Minonzio, F | 1 |
| Delbini, P | 1 |
| Bianchi, A | 1 |
| Tanner, MA | 1 |
| Smith, GC | 1 |
| Westwood, MA | 1 |
| Agus, A | 1 |
| Roughton, M | 1 |
| Assomull, R | 1 |
| Nair, SV | 1 |
| Walker, JM | 1 |
| Klinz, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferiprone and Cardiac Failure
| Article | Year |
|---|---|
T2* magnetic resonance and myocardial iron in thalassemia.
Topics: Adult; Calibration; Cardiomyopathies; Chelation Therapy; Child; Cohort Studies; Combined Modality Th | 2005 |
4 trials available for deferiprone and Cardiac Failure
| Article | Year |
|---|---|
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Heart Failure | 2013 |
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Comorbidity; Deferasirox; Deferiprone; Deferoxamine; Drug Therap | 2012 |
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Topics: Administration, Oral; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Clinical Protocols; Com | 2006 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2007 |
13 other studies available for deferiprone and Cardiac Failure
| Article | Year |
|---|---|
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluati | 2020 |
Life-Threatening Drug-Induced Liver Injury in a Patient with β-Thalassemia Major and Severe Iron Overload on Polypharmacy.
Topics: Adrenergic beta-Antagonists; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver In | 2018 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Defer | 2013 |
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Topics: Cardiomyopathies; Deferiprone; Deferoxamine; Ferritins; Heart Failure; Hemochromatosis; Hemochromato | 2016 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D | 2004 |
Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Synergism; Drug Therapy, Combination; Heart | 2005 |
Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferiprone; Def | 2005 |
[Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Heart Failure; Humans; Iron C | 2006 |
Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Failure; Hemosi | 2006 |
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Mod | 2006 |
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomegaly; Cardiomyopathies; Chelation Therapy; Cohort Studi | 2006 |
Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH).
Topics: Adult; Amino Acid Substitution; Antimicrobial Cationic Peptides; Atrial Fibrillation; Chelation Ther | 2007 |
[Marked hemosiderosis in myelodysplastic syndrome].
Topics: Aged; Deferiprone; Diabetes Mellitus, Type 2; Erythrocyte Transfusion; Heart Failure; Hemosiderosis; | 1999 |